clinical trials glp 1 Timeline of GLP-1 discovery and development. (a) Key events in GLP-1 receptor agonists and cardiovascular
Description
The challenge is that this route is structurally hard to monetise, he says
In three separate SUSTAIN trials, semaglutide 1 mg conferred a greater weight loss among adults with type 2 diabetes than exenatide 2 mg (Bydureon, AstraZeneca), dulaglutide 1.5 mg (Trulicity, Eli Lilly) and liraglutide 1.8 mg (Saxenda, Novo Nordisk)
J Biol Chem 270: 26488-26496, 1995
Mistake 4: Increasing dose too quickly Impatience drives this one
